Uptake of HIV Preexposure Prophylaxis Among Commercially Insured Persons—United States, 2010–2014 | Zendy

Hsiu Wu | Zendy; Maria C.B. Mendoza | Zendy; Ya-Lin A. Huang | Zendy; Tameka Hayes | Zendy; Dawn K. Smith | Zendy; Karen W. Hoover | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Uptake of HIV Preexposure Prophylaxis Among Commercially Insured Persons—United States, 2010–2014

Author(s) -

Hsiu Wu,

Maria C.B. Mendoza,

Ya-Lin A. Huang,

Tameka Hayes,

Dawn K. Smith,

Karen W. Hoover

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw701

Subject(s) - medicine , pre exposure prophylaxis , emtricitabine , human immunodeficiency virus (hiv) , psychological intervention , tenofovir , pharmacy , family medicine , demography , men who have sex with men , antiretroviral therapy , viral load , syphilis , psychiatry , sociology

Daily, oral use of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) for preexposure prophylaxis (PrEP) is an effective strategy to prevent acquisition of human immunodeficiency virus (HIV) infection. It is important to monitor PrEP uptake at the national level to increase our understanding of trends in its utilization, but national HIV surveillance data do not include PrEP uptake. Our objective was to develop feasible methods to estimate PrEP uptake and to estimate uptake each year among commercially insured persons during 2010-2014.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research